BIO-RAD LABORATORIES-A (BIO)
US0905722072 - Common Stock
ChartMill assigns a Buy % Consensus number of 80% to BIO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 418. This target is 51.67% above the current price.
BIO was analyzed by 10 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about BIO.
In the previous month the buy percentage consensus was at a similar level.
BIO was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-03 | Citigroup | Downgrade | Buy -> Neutral |
| 2024-02-16 | UBS | Maintains | Buy -> Buy |
| 2024-02-16 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-12-07 | UBS | Initiate | Buy |
| 2023-08-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2023-08-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-08-04 | Credit Suisse | Maintains | Outperform -> Outperform |
| 2023-06-16 | Wells Fargo | Initiate | Overweight |
| 2023-05-08 | RBC Capital | Maintains | Outperform |
| 2023-05-08 | Citigroup | Maintains | Buy |
| 2023-05-05 | Credit Suisse | Maintains | Outperform |
| 2023-02-17 | RBC Capital | Maintains | Outperform |
| 2023-02-17 | Credit Suisse | Maintains | Outperform |
| 2022-12-07 | RBC Capital | Initiate | Outperform |
| 2022-10-28 | Credit Suisse | Maintains | Outperform |
| 2022-08-25 | Credit Suisse | Initiate | Outperform |
| 2022-07-08 | Citigroup | Maintains | Buy |
| 2021-07-30 | Wells Fargo | Maintains | Overweight |
| 2021-02-12 | Citigroup | Maintains | Buy |